Abstract
Rapid developments in molecular genetic technology and research have swiftly advanced our understanding of neuro-oncology. As a consequence, the WHO invited their expert panels to revise the current classification system of brain tumours and to introduce, for the first time, a molecular genetic approach for selected tumour entities, thus setting a new gold standard in histopathology. The revised 5th edition of the 'blue book' was released in May 2016 and will have a major impact in stratifying diagnosis and treatment. However, low-grade neuroepithelial tumours that present with early-onset focal epilepsy and are mostly seen in children and young adults (previously designated as long-term epilepsy-associated neuroepithelial tumours, LEAT) lack such innovative clinicopathological and molecular genetic tools. The Neuropathology Task Force of the International League against Epilepsy will critically discuss this issue, and will offer perspectives on how to decipher and validate clinically meaningful LEAT entities using the current WHO approach that integrates clinicopathological and genetic classification systems.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. (eds) WHO Classification of Tumours of the Central Nervous System 5th revised edn (International Agency for Research on Cancer, 2016).
Louis, D. N. et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 131, 803–820 (2016).
Louis, D. N. et al. International Society Of Neuropathology — Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 24, 429–435 (2014).
Reuss, D. E. et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. Acta Neuropathol. 129, 133–146 (2015).
Jenkins, R. B. et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res. 66, 9852–9861 (2006).
Cairncross, J. G. et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl Cancer Inst. 90, 1473–1479 (1998).
Reifenberger, G. et al. in WHO classification of Tumours of the Central Nervous System 4th revised edn (eds Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavanee, W. K.) 60–62 (International Agency for Research on Cancer, 2007).
Reifenberger, J. et al. Molecular-genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am. J. Pathol. 145, 1175–1190 (1994).
Stupp, R. et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 352, 987–996 (2005).
Hegi, M. E. et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 352, 997–1003 (2005).
Yan, H. et al. IDH1 and IDH2 mutations in gliomas. N. Engl. J. Med. 360, 765–773 (2009).
Parsons, D. W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807–1812 (2008).
Capper, D. et al. Application of mutant IDH1 antibody to differentiate diffuse glioma from nonneoplastic central nervous system lesions and therapy-induced changes. Am. J. Surg. Pathol. 34, 1199–1204 (2010).
Capper, D. et al. Characterization of R132H mutation-specific IDH1 antibody binding in brain tumors. Brain Pathol. 20, 245–254 (2010).
Wick, W. et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J. Clin. Oncol. 27, 5874–5880 (2009).
Buckner, J. C. et al. Radiation plus procarbazine, CCNU, and vincristine in low-grade glioma. N. Engl. J. Med. 374, 1344–1355 (2016).
Sturm, D. et al. New brain tumor entities emerge from molecular classification of CNS-PNETs. Cell 164, 1060–1072 (2016).
Weller, M. et al. MGMT promoter methylation is a strong prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: the DIRECTOR trial. Clin. Cancer Res. 21, 2057–2064 (2015).
Luyken, C. et al. The spectrum of long-term epilepsy-associated tumors: long-term seizure and tumor outcome and neurosurgical aspects. Epilepsia 44, 822–830 (2003).
Blumcke, I., Aronica, E., Urbach, H., Alexopoulos, A. & Gonzalez-Martinez, J. A. A neuropathology-based approach to epilepsy surgery in brain tumors and proposal for a new terminology use for long-term epilepsy-associated brain tumors. Acta Neuropathol. 128, 39–54 (2014).
Castel, D. et al. Histone H3F3A and HIST1H3B K27M mutations define two subgroups of diffuse intrinsic pontine gliomas with different prognosis and phenotypes. Acta Neuropathol. 130, 815–827 (2015).
Bodi, I. et al. Two cases of multinodular and vacuolating neuronal tumour. Acta Neuropathol. Commun. 2, 7 (2014).
Yamaguchi, M. et al. Multinodular and vacuolating neuronal tumor affecting amygdala and hippocampus: a quasi-tumor? Pathol. Int. 66, 34–41 (2016).
Nagaishi, M. et al. Localized overexpression of alpha-internexin within nodules in multinodular and vacuolating neuronal tumors. Neuropathology 35, 561–568 (2015).
Fukushima, S. et al. Multinodular and vacuolating neuronal tumor of the cerebrum. Brain Tumor Pathol. 32, 131–136 (2015).
Huse, J. T. et al. Multinodular and vacuolating neuronal tumors of the cerebrum: 10 cases of a distinctive seizure-associated lesion. Brain Pathol. 23, 515–524 (2013).
Reifenberger, G. & Louis, D. N. Oligodendroglioma: toward molecular definitions in diagnostic neuro-oncology. J. Neuropathol. Exp. Neurol. 62, 111–126 (2003).
Giannini, C. et al. Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J. Neuropathol. Exp. Neurol. 60, 248–262 (2001).
van den Bent, M. J. et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clin. Cancer Res. 16, 1597–1604 (2010).
Weller, M. et al. Combined 1p/19q loss in oligodendroglial tumors: predictive or prognostic biomarker? Clin. Cancer Res. 13, 6933–6937 (2007).
Thom, M., Blumcke, I. & Aronica, E. Long-term epilepsy-associated tumors. Brain Pathol. 22, 350–379 (2012).
Fisher, R. S. et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55, 475–482 (2014).
Kwan, P. et al. Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies. Epilepsia 51, 1069–1077 (2010).
Blumcke, I. et al. International recommendation for a comprehensive neuropathologic workup of epilepsy surgery brain tissue: a consensus Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia 57, 348–358 (2016).
Wiebe, S., Blume, W. T., Girvin, J. P. & Eliasziw, M. A randomized, controlled trial of surgery for temporal-lobe epilepsy. N. Engl. J. Med. 345, 311–318 (2001).
Jemal, A. et al. Cancer statistics, 2006. CA Cancer J. Clin. 56, 106–130 (2006).
Blumcke, I. & Wiestler, O. D. Gangliogliomas: an intriguing tumor entity associated with focal epilepsies. J. Neuropathol. Exp. Neurol. 61, 575–584 (2002).
Thom, M. et al. One hundred and one dysembryoplastic neuroepithelial tumors: an adult epilepsy series with immunohistochemical, molecular genetic, and clinical correlations and a review of the literature. J. Neuropathol. Exp. Neurol. 70, 859–878 (2011).
Holthausen, H. & Blumcke, I. Epilepsy-associated tumours: what epileptologists should know about neuropathology, terminology, and classification systems. Epileptic Disord. 18, 240–251 (2016).
Horbinski, C. et al. Isocitrate dehydrogenase 1 analysis differentiates gangliogliomas from infiltrative gliomas. Brain Pathol. 21, 564–574 (2011).
Prabowo, A. S. et al. Landscape of chromosomal copy number aberrations in gangliogliomas and dysembryoplastic neuroepithelial tumours. Neuropathol. Appl. Neurobiol. 41, 743–755 (2015).
Qaddoumi, I. et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. Acta Neuropathol. 131, 833–845 (2016).
Dougherty, M. J. et al. Activating mutations in BRAF characterize a spectrum of pediatric low-grade gliomas. Neuro Oncol. 12, 621–630 (2010).
Schindler, G. et al. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma. Acta Neuropathol. 121, 397–405 (2011).
Ramkissoon, L. A. et al. Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor MYBL1. Proc. Natl Acad. Sci. USA 110, 8188–8193 (2013).
Roth, J. J. et al. Diagnostic application of high resolution single nucleotide polymorphism array analysis for children with brain tumors. Cancer Genet. 207, 111–123 (2014).
Cruz, G. R. et al. Analysis of KIAA1549–BRAF fusion gene expression and IDH1/IDH2 mutations in low grade pediatric astrocytomas. J. Neurooncol. 117, 235–242 (2014).
Prabowo, A. S. et al. BRAF V600E mutation is associated with mTOR signaling activation in glioneuronal tumors. Brain Pathol. 24, 52–66 (2014).
Zhang, J. et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas. Nat. Genet. 45, 602–612 (2013).
Chappe, C. et al. Dysembryoplastic neuroepithelial tumors share with pleomorphic xanthoastrocytomas and gangliogliomas BRAF Mutation and expression. Brain Pathol. 23, 574–583 (2013).
Rivera, B. et al. Germline and somatic FGFR1 abnormalities in dysembryoplastic neuroepithelial tumors. Acta Neuropathol. 131, 847–863 (2016).
Korshunov, A. et al. Combined molecular analysis of BRAF and IDH1 distinguishes pilocytic astrocytoma from diffuse astrocytoma. Acta Neuropathol. 118, 401–405 (2009).
Wang, M. et al. Monomorphous angiocentric glioma: a distinctive epileptogenic neoplasm with features of infiltrating astrocytoma and ependymoma. J. Neuropathol. Exp. Neurol. 64, 875–881 (2005).
Holsken, A. et al. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles. Acta Neuropathol. Commun. 4, 20 (2016).
Johann, P. D. et al. Atypical teratoid/rhabdoid tumors are comprised of three epigenetic subgroups with distinct enhancer landscapes. Cancer Cell 29, 379–393 (2016).
Pajtler, K. W. et al. Molecular classification of ependymal tumors across all CNS compartments, histopathological grades, and age groups. Cancer Cell 27, 728–743 (2015).
Capper, D. et al. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody. Acta Neuropathol. 122, 11–19 (2011).
Koelsche, C. et al. Mutant BRAF V600E protein in ganglioglioma is predominantly expressed by neuronal tumor cells. Acta Neuropathol. 125, 891–900 (2013).
Majores, M. et al. Tumor recurrence and malignant progression of gangliogliomas. Cancer 113, 3355–3363 (2008).
Blumcke, I. et al. The CD34 epitope is expressed in neoplastic and malformative lesions associated with chronic, focal epilepsies. Acta Neuropathol. 97, 481–490 (1999).
Blumcke, I. et al. The clinico-pathological spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission. Epilepsia 52, 158–174 (2011).
Blumcke, I. et al. International consensus classification of hippocampal sclerosis in temporal lobe epilepsy: a Task Force report from the ILAE Commission on Diagnostic Methods. Epilepsia 54, 1315–1329 (2013).
Coras, R. et al. Good interobserver and intraobserver agreement in the evaluation of the new ILAE classification of focal cortical dysplasias. Epilepsia 53, 1341–1348 (2012).
Blumcke, I. et al. Distinct expression pattern of microtubule-associated protein-2 in human oligodendrogliomas and glial precursor cells. J. Neuropathol. Exp. Neurol. 60, 984–993 (2001).
Schramm, J., Luyken, C., Urbach, H., Fimmers, R. & Blumcke, I. Evidence for a clinically distinct new subtype of grade II astrocytomas in patients with long-term epilepsy. Neurosurgery 55, 340–347 (2004).
Blumcke, I., Luyken, C., Urbach, H., Schramm, J. & Wiestler, O. D. An isomorphic subtype of long-term epilepsy-associated astrocytomas associated with benign prognosis. Acta Neuropathol. 107, 381–388 (2004).
Zülch, K. J. Histological Typing of Tumours of the Central Nervous System (World Health Organization, 1979).
Kleihues, P., Burger, P. C. & Scheithauer, B. W. (eds) Histological Typing of Tumors of the Central Nervous System (Springer, 1993).
Kleihues, P. & Cavenee, W. K. (eds) Pathology and Genetics of Tumors of the Nervous System (International Agency for Research on Cancer, 2000).
Louis, D. N., Ohgaki, H., Wiestler, O. D. & Cavenee, W. K. (eds) WHO Classification of Tumors of the Central Nervous System 4th revised edn (International Agency for Research on Cancer, 2007).
Agarwal, S. et al. Extraventricular neurocytomas: a morphological and histogenetic consideration. A study of six cases. Pathology 43, 327–334 (2011).
Capper, D. et al. Mutation-specific IDH1 antibody differentiates oligodendrogliomas and oligoastrocytomas from other brain tumors with oligodendroglioma-like morphology. Acta Neuropathol. 121, 241–252 (2011).
Horstmann, S. et al. Genetic and expression profiles of cerebellar liponeurocytomas. Brain Pathol. 14, 281–289 (2004).
Bridge, J. A. et al. Identification of a novel, recurrent SLC44A1-PRKCA fusion in papillary glioneuronal tumor. Brain Pathol. 23, 121–128 (2013).
Solis, O. E. et al. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. J. Neurooncol. 102, 477–484 (2011).
Gessi, M. et al. FGFR1 mutations in rosette-forming glioneuronal tumors of the fourth ventricle. J. Neuropathol. Exp. Neurol. 73, 580–584 (2014).
Gessi, M. et al. Absence of KIAA1549-BRAF fusion in rosette-forming glioneuronal tumors of the fourth ventricle (RGNT). J. Neurooncol. 110, 21–25 (2012).
Rodriguez, F. J. et al. Disseminated oligodendroglial-like leptomeningeal tumor of childhood: a distinctive clinicopathologic entity. Acta Neuropathol. 124, 627–641 (2012).
Rodriguez, F. J. et al. High rate of concurrent BRAF-KIAA1549 gene fusion and 1p deletion in disseminated oligodendroglioma-like leptomeningeal neoplasms (DOLN). Acta Neuropathol. 129, 609–610 (2015).
Preuss, M. et al. Disseminated oligodendroglial-like leptomeningeal tumors: preliminary diagnostic and therapeutic results for a novel tumor entity [corrected]. J. Neurooncol 124, 65–74 (2015).
Acknowledgements
Members of the ILAE Neuropathology Task Force have been partially supported by the Seventh Framework Programme of the European Commission (DESIRE GA # 602531 to I.B.; EPITARGET GA # 602102 to A.B., and E.A.; EPISTOP # 602391 to E.A.). E.A. has received funding from KIKA (Stichting Kinderen Kankervrij) and Stichting AMC Foundation. T.J. has received funding from the Brain Tumour Charity, Children with Cancer, Great Ormond Street Children's Charity and NIHR. H.M. has received funding from the Japan Epilepsy Research Foundation (JERF) (H25-003).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Supplementary information
Supplementary information S1 (table)
Changes in WHO tumour classification introduced by the 5th edition (2016) (PDF 74 kb)
Rights and permissions
About this article
Cite this article
Blümcke, I., Aronica, E., Becker, A. et al. Low-grade epilepsy-associated neuroepithelial tumours — the 2016 WHO classification. Nat Rev Neurol 12, 732–740 (2016). https://doi.org/10.1038/nrneurol.2016.173
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2016.173
This article is cited by
-
Germline BRCA2 pathogenic variants in pediatric ganglioglioma: Case report and review of the literature
Child's Nervous System (2024)
-
Clinicopathological features of dysembryoplastic neuroepithelial tumor: a case series
Journal of Medical Case Reports (2023)
-
Automated epilepsy seizure detection from EEG signal based on hybrid CNN and LSTM model
Signal, Image and Video Processing (2023)
-
Deep histopathology genotype–phenotype analysis of focal cortical dysplasia type II differentiates between the GATOR1-altered autophagocytic subtype IIa and MTOR-altered migration deficient subtype IIb
Acta Neuropathologica Communications (2023)
-
Ganglioglioma with adverse clinical outcome and atypical histopathological features were defined by alterations in PTPN11/KRAS/NF1 and other RAS-/MAP-Kinase pathway genes
Acta Neuropathologica (2023)